-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Tops Q3 EPS by 24c
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Misses Q2 EPS by 172c
-
-
-
-
-
-
-
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
-
-
-
-
-
-
-
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
-
-
-
-
-
-
-
Pfizer (PFE) and Biohaven’s (BHVN) VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
-
1,199,634 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

